AstraZeneca: FDA approval for Farxiga

(CercleFinance.com) - AstraZeneca announced last Friday that the US Food and Drug Administration (FDA) has approved its drug Farxiga for the treatment of chronic kidney disease.


The FDA's approval covers both patients with and without type 2 diabetes, the company said in a statement.

In its press release, the biopharmaceutical group considers that the FDA approval represents the most significant advance in the treatment of the disease for over 20 years.

AstraZeneca estimates that 37 million people in the US are currently affected by the disease.

In Phase III clinical trials, Farxiga was shown to slow the worsening of kidney function in treated patients by 39% compared to placebo.



Copyright (c) 2021 CercleFinance.com. All rights reserved.